Annovis BioANVS
About: Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Employees: 6
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
67% more capital invested
Capital invested by funds: $5.7M [Q2] → $9.53M (+$3.83M) [Q3]
13% more funds holding
Funds holding: 31 [Q2] → 35 (+4) [Q3]
0.2% more ownership
Funds ownership: 8.86% [Q2] → 9.06% (+0.2%) [Q3]
72% less call options, than puts
Call options by funds: $3.33M | Put options by funds: $12M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
D. Boral Capital Jason Kolbert 31% 1-year accuracy 67 / 214 met price target | 582%upside $21 | Buy Maintained | 11 Nov 2024 |
HC Wainwright & Co. Raghuram Selvaraju 40% 1-year accuracy 130 / 329 met price target | 874%upside $30 | Buy Reiterated | 11 Nov 2024 |
Financial journalist opinion
Based on 5 articles about ANVS published over the past 30 days









